Abstract
The epidermal growth factor receptors EGFR and HER2 are the main targets for tyrosine kinase inhibitors (TKIs). The quinazoline derivative lapatinib (LAP) is used since 2007 as dual TKI in the treatment of metastatic breast cancer and currently, it is used as an oral anticancer drug for the treatment of solid tumors such as breast and lung cancer. Although hepatotoxicity is its main side effect, it makes sense to investigate the ability of LAP to induce photosensitivity reactions bearing in mind that BRAF (serine/threonine-protein kinase B-Raf) inhibitors display a considerable phototoxic potential and that afloqualone, a quinazoline-marketed drug, causes photodermatosis. Metabolic bioactivation of LAP by CYP3A4 and CYP3A5 leads to chemically reactive N-dealkylated (N-LAP) and O-dealkylated (O-LAP) derivatives. In this context, the aim of the present work is to explore whether LAP and its N- and O-dealkylated metabolites can induce photosensitivity disorders by evaluating their photo(geno)toxicity through in vitro studies, including cell viability as well as photosensitized protein and DNA damage. As a matter of fact, our work has demonstrated that not only LAP, but also its metabolite N-LAP have a clear photosensitizing potential. They are both phototoxic and photogenotoxic to cells, as revealed by the 3T3 NRU assay and the comet assay, respectively. By contrast, the O-LAP does not display relevant photobiological properties. Remarkably, the parent drug LAP shows the highest activity in membrane phototoxicity and protein oxidation, whereas N-LAP is associated with the highest photogenotoxicity, through oxidation of purine bases, as revealed by detection of 8-Oxo-dG.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abo-Zeid MAM, Abo-Elfadl MT, Gamal-Eldeen AM (2019) Evaluation of lapatinib cytotoxicity and genotoxicity on MDA-MB-231 breast cancer cell line. Environ Toxicol Pharmacol 71:103207. https://doi.org/10.1016/j.etap.2019.103207
Agundez JAG, Garcia-Martin E, Garcia-Lainez G, Miranda MA, Andreu I (2020) Photomutagenicity of chlorpromazine and its N-demethylated metabolites assessed by NGS. Sci Rep 10(1):6879. https://doi.org/10.1038/s41598-020-63651-y
Cadet J, Davies KJA (2017) Oxidative DNA damage and repair: an introduction. Free Radic Biol Med 107:2–12. https://doi.org/10.1016/j.freeradbiomed.2017.03.030
Castellino S, O'Mara M, Koch K, Borts DJ, Bowers GD, MacLauchlin C (2012) Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity. Drug Metab Dispos 40(1):139–150. https://doi.org/10.1124/dmd.111.040949
Ding J, Yao Y, Huang G et al (2020) Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib. Cancer Lett 475:53–64. https://doi.org/10.1016/j.canlet.2020.01.032
Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. https://doi.org/10.1002/ijc.29210
Frenel JS, Bourbouloux E, Berton-Rigaud D, Sadot-Lebouvier S, Zanetti A, Campone M (2009) Lapatinib in metastatic breast cancer. Womens Health (Lond) 5(6):603–612. https://doi.org/10.2217/whe.09.54
Garcia-Lainez G, Martinez-Reig AM, Limones-Herrero D, Consuelo Jimenez M, Miranda MA, Andreu I (2018) Photo(geno)toxicity changes associated with hydroxylation of the aromatic chromophores during diclofenac metabolism. Toxicol Appl Pharmacol 341:51–55. https://doi.org/10.1016/j.taap.2018.01.005
Gavilá J, De La Haba J, Bermejo B et al (2020) A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study. Clin Transl Oncol 22(3):420–428. https://doi.org/10.1007/s12094-019-02145-4
Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743. https://doi.org/10.1056/NEJMoa064320
Gomez HL, Doval DC, Chavez MA et al (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26(18):2999–3005. https://doi.org/10.1200/JCO.2007.14.0590
Heppt MV, Clanner-Engelshofen BM, Marsela E et al (2020) Comparative analysis of the phototoxicity induced by BRAF inhibitors and alleviation through antioxidants. Photodermatol Photoimmunol Photomed 36(2):126–134. https://doi.org/10.1111/phpp.12520
Higa GM, Abraham J (2007) Lapatinib in the treatment of breast cancer. Expert Rev Anticancer Ther 7(9):1183–1192. https://doi.org/10.1586/14737140.7.9.1183
Huijberts S, van Geel R, van Brummelen EMJ et al (2020) Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. Cancer Chemother Pharmacol 85(5):917–930. https://doi.org/10.1007/s00280-020-04066-4
Kabir MZ, Mukarram AK, Mohamad SB, Alias Z, Tayyab S (2016) Characterization of the binding of an anticancer drug, lapatinib to human serum albumin. J Photochem Photobiol B 160:229–239. https://doi.org/10.1016/j.jphotobiol.2016.04.005
Kopper L (2008) Lapatinib: a sword with two edges. Pathol Oncol Res 14(1):1–8. https://doi.org/10.1007/s12253-008-9018-z
Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A (2015) Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol 72(2):203–218. https://doi.org/10.1016/j.jaad.2014.07.032
Medina PJ, Goodin S (2008) Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 30(8):1426–1447. https://doi.org/10.1016/j.clinthera.2008.08.008
Melhuish WH (1961) Quantum efficiencies of fluorescence of organic substances: effect of solvent and concentration of the fluorescent solute. J Phys Chem 65(2):229–235. https://doi.org/10.1021/j100820a009
Mendelsohn J, Baselga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19(56):6550–6565. https://doi.org/10.1038/sj.onc.1204082
Moon JY, Han JM, Seo I, Gwak HS (2019) Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity. Breast Cancer Res Treat 178(1):239–244. https://doi.org/10.1007/s10549-019-05382-x
Nolting M, Schneider-Merck T, Trepel M (2014) Lapatinib. Recent Results Cancer Res 201:125–143. https://doi.org/10.1007/978-3-642-54490-3_7
OECD (2004) OECD Guidelines for the Testing of Chemicals Test No. 432: In Vitro 3T3 NRU Phototoxicity Test. https://doi.org/10.1787/20745788
Palumbo F, Garcia-Lainez G, Limones-Herrero D et al (2016) Enhanced photo(geno)toxicity of demethylated chlorpromazine metabolites. Toxicol Appl Pharmacol 313:131–137. https://doi.org/10.1016/j.taap.2016.10.024
Parham LR, Briley LP, Li L et al (2016) Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01. Pharmacogenomics J 16(2):180–185. https://doi.org/10.1038/tpj.2015.40
Rayane Mohamed FS, Sidibe J, Bararpour N, Desmeules J, Ausburger M, Daali Y, Thomas A (2018) Detection and identification of reactive drug metabolites leading to idiosyncratic toxicity: lapatinib as a case example. J Drug Metab Toxicol 9(3):1–6. https://doi.org/10.4172/2157-7609.1000242
Schroeder RL, Stevens CL, Sridhar J (2014) Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer. Molecules 19(9):15196–15212. https://doi.org/10.3390/molecules190915196
Spector N, Xia W, El-Hariry I, Yarden Y, Bacus S (2007) HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res 9(2):205. https://doi.org/10.1186/bcr1652
Spraggs CF, Budde LR, Briley LP et al (2011) HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 29(6):667–673. https://doi.org/10.1200/jco.2010.31.3197
Tokura Y, Ogai M, Yagi H, Takigawa M (1994) Afloqualone photosensitivity: immunogenicity of afloqualone-photomodified epidermal cells. Photochem Photobiol 60(3):262–267. https://doi.org/10.1111/j.1751-1097.1994.tb05102.x
Towles JK, Clark RN, Wahlin MD, Uttamsingh V, Rettie AE, Jackson KD (2016) Cytochrome P450 3A4 and CYP3A5-catalyzed bioactivation of lapatinib. Drug Metab Dispos 44(10):1584–1597. https://doi.org/10.1124/dmd.116.070839
Wang H (2014) Lapatinib for the treatment of breast cancer in the People’s Republic of China. Onco Targets Ther 7:1367–1373. https://doi.org/10.2147/OTT.S60586
Acknowledgements
This study was funded by the Carlos III Institute (ISCIII) of Health (Grants: PI16/01877, CPII16/00052, ARADyAL RD16/0006/0030) co-funded by European Regional Development Fund, the Spanish Government (RYC-2015-17737, CTQ2017-89416-R,) and Generalitat Valenciana (Prometeo/2017/075). We would also like to thank IIS La Fe Microscopy Unit for technical assistance.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
García-Lainez, G., Vayá, I., Marín, M.P. et al. In vitro assessment of the photo(geno)toxicity associated with Lapatinib, a Tyrosine Kinase inhibitor. Arch Toxicol 95, 169–178 (2021). https://doi.org/10.1007/s00204-020-02880-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-020-02880-6